Impact of a pharmaceutical algorithm on patients with upper-gastrointestinal symptoms: A pre-post intervention study

• DOI: 10.1016/j.ypmed.2024.107885
• Publication Date: 2024-02-03T16:04:54Z
• Authors: María Puig-Moltó; Blanca Lumbreras; Juan Manuel Mendive; Elsa López-Pintor
• Keywords: Heartburn

To evaluate the algorithm impact on upper gastrointestinal patients' symptoms (PROMs) and satisfaction with pharmaceutical care received (PREMs). The was previously developed by clinicians pharmacists, through a pre-post intervention study in Spain (June–October 2022). We included 1221 patients who were seeking advice and/or medication for at 134 community pharmacies. Patients' sociodemographic clinical variables assessed baseline classified accordance Gastroesophageal Reflux Disease Impact Scale (GIS) into either epigastric, retrosternal or overlapping symptoms. Interventions medical referral; education healthy habits; prescription of an OTC treatment non-pharmacologic prescription. Fourteen days later, through: a) change GIS score, b) . Most reported (660, 54.0%), 171 (14.0%) epigastric 390 (32.0%) Patients did not show difference score after while those (mean 1.09 (4.28 SD), p < 0.001 mean 3.18 (6.01 0.001, respectively). habits pharmacological (antiacids monotherapy alginates-antiacids) showed increase score. over 99.2% sample. Implementation upper-gastrointestinal Community pharmacies had positive symptoms, quality life, received.